This is best illustrated with the first adeno-associated virus (AAV)-based gene therapy in the treatment of mutated retinoid isomerohydrolase 65 (RPE65) in Leber congenital amaurosis-2 (LCA-2) [50]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.